Free Trial

Phathom Pharmaceuticals (PHAT) Financials

Phathom Pharmaceuticals logo
$4.69 -0.01 (-0.21%)
Closing price 04:00 PM Eastern
Extended Trading
$4.72 +0.03 (+0.64%)
As of 05:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for Phathom Pharmaceuticals

Annual Income Statements for Phathom Pharmaceuticals

This table shows Phathom Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Income / (Loss) Attributable to Common Shareholders
-334 -202 -198
Consolidated Net Income / (Loss)
-334 -202 -198
Net Income / (Loss) Continuing Operations
-334 -202 -198
Total Pre-Tax Income
-334 -202 -198
Total Operating Income
-277 -167 -172
Total Gross Profit
47 0.52 0.00
Total Revenue
55 0.68 0.00
Operating Revenue
55 0.68 0.00
Total Cost of Revenue
7.97 0.17 0.00
Operating Cost of Revenue
7.97 0.17 0.00
Total Operating Expenses
325 168 172
Selling, General & Admin Expense
291 118 101
Research & Development Expense
34 50 71
Total Other Income / (Expense), net
-57 -34 -25
Interest Expense
72 42 27
Interest & Investment Income
15 7.88 2.13
Other Income / (Expense), net
-0.01 -0.19 -0.11
Basic Earnings per Share
($5.29) ($3.93) ($5.05)
Weighted Average Basic Shares Outstanding
63.18M 51.29M 39.12M
Diluted Earnings per Share
($5.29) ($3.93) ($5.05)
Weighted Average Diluted Shares Outstanding
63.18M 51.29M 39.12M
Weighted Average Basic & Diluted Shares Outstanding
69.64M 58.48M 41.97M

Quarterly Income Statements for Phathom Pharmaceuticals

This table shows Phathom Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders
-74 -86 -91 -83 -80 -43 -41 -38 -55 -51
Consolidated Net Income / (Loss)
-74 -86 -91 -83 -80 -43 -41 -38 -55 -51
Net Income / (Loss) Continuing Operations
-74 -86 -91 -83 -80 -43 -41 -38 -55 -51
Total Pre-Tax Income
-74 -86 -91 -83 -80 -43 -41 -38 -55 -51
Total Operating Income
-59 -71 -77 -70 -70 -36 -32 -30 -47 -43
Total Gross Profit
26 14 5.95 1.49 0.52 0.00 0.00 0.00 - 0.00
Total Revenue
30 16 7.32 1.91 0.68 0.00 0.00 0.00 - 0.00
Operating Revenue
30 16 7.32 1.91 0.68 0.00 0.00 0.00 - -
Total Cost of Revenue
3.82 2.36 1.38 0.43 0.17 0.00 0.00 0.00 - 0.00
Operating Cost of Revenue
3.82 2.36 1.38 0.43 0.17 0.00 0.00 0.00 - -
Total Operating Expenses
85 85 83 71 70 36 32 30 47 43
Selling, General & Admin Expense
77 76 76 62 57 23 19 19 31 24
Research & Development Expense
8.58 8.69 7.38 9.43 13 12 13 11 16 19
Total Other Income / (Expense), net
-15 -15 -14 -13 -9.70 -7.58 -9.26 -7.74 -8.41 -8.56
Interest Expense
19 18 18 17 13 10 9.62 9.22 9.60 9.28
Interest & Investment Income
3.51 3.71 3.62 4.31 3.35 2.72 0.35 1.46 1.29 0.73
Other Income / (Expense), net
0.05 -0.01 -0.01 -0.04 -0.01 -0.20 0.00 0.02 -0.09 -0.01
Basic Earnings per Share
($0.99) ($1.32) ($1.56) ($1.42) ($1.44) ($0.76) ($0.84) ($0.89) ($1.33) ($1.32)
Weighted Average Basic Shares Outstanding
63.18M 64.63M 58.56M 58.37M 51.29M 56.78M 48.50M 42.35M 39.12M 38.82M
Diluted Earnings per Share
($0.99) ($1.32) ($1.56) ($1.42) ($1.44) ($0.76) ($0.84) ($0.89) ($1.33) ($1.32)
Weighted Average Diluted Shares Outstanding
63.18M 64.63M 58.56M 58.37M 51.29M 56.78M 48.50M 42.35M 39.12M 38.82M
Weighted Average Basic & Diluted Shares Outstanding
69.64M 68.38M 59.59M 58.54M 58.48M 57.25M 56.80M 43.61M 41.97M 41.62M

Annual Cash Flow Statements for Phathom Pharmaceuticals

This table details how cash moves in and out of Phathom Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Change in Cash & Equivalents
-84 228 -28
Net Cash From Operating Activities
-267 -138 -147
Net Cash From Continuing Operating Activities
-267 -138 -147
Net Income / (Loss) Continuing Operations
-334 -202 -198
Consolidated Net Income / (Loss)
-334 -202 -198
Depreciation Expense
0.80 0.58 0.62
Amortization Expense
2.19 1.88 2.11
Non-Cash Adjustments To Reconcile Net Income
80 75 41
Changes in Operating Assets and Liabilities, net
-15 -14 7.08
Net Cash From Investing Activities
-0.14 -1.63 -1.04
Net Cash From Continuing Investing Activities
-0.14 -1.63 -1.04
Purchase of Property, Plant & Equipment
-0.14 -1.63 -1.04
Net Cash From Financing Activities
183 368 120
Net Cash From Continuing Financing Activities
183 368 120
Issuance of Debt
181 181 0.00
Issuance of Common Equity
0.00 14 25
Other Financing Activities, net
1.60 173 95
Cash Interest Paid
17 11 7.03

Quarterly Cash Flow Statements for Phathom Pharmaceuticals

This table details how cash moves in and out of Phathom Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents
-37 58 -46 -59 168 -33 119 -26 -41 -11
Net Cash From Operating Activities
-63 -64 -71 -69 -44 -32 -22 -40 -41 -35
Net Cash From Continuing Operating Activities
-63 -64 -71 -69 -44 -32 -22 -40 -41 -35
Net Income / (Loss) Continuing Operations
-74 -86 -91 -83 -80 -43 -41 -38 -55 -51
Consolidated Net Income / (Loss)
-74 -86 -91 -83 -80 -43 -41 -38 -55 -51
Depreciation Expense
0.19 0.19 0.20 0.21 0.19 0.12 0.12 0.15 0.17 0.18
Amortization Expense
0.63 0.59 0.50 0.47 0.57 0.54 0.27 0.50 0.50 0.56
Non-Cash Adjustments To Reconcile Net Income
19 20 21 20 34 14 14 14 13 12
Changes in Operating Assets and Liabilities, net
-9.08 1.34 -0.67 -7.07 1.29 -3.12 4.38 -16 -0.07 2.91
Net Cash From Investing Activities
-0.01 -0.04 -0.05 -0.04 -0.48 -0.94 -0.01 -0.21 -0.41 -0.13
Net Cash From Continuing Investing Activities
-0.01 -0.04 -0.05 -0.04 -0.48 -0.94 -0.01 -0.21 -0.41 -0.13
Purchase of Property, Plant & Equipment
-0.01 -0.04 -0.05 -0.04 -0.48 -0.94 -0.01 -0.21 -0.41 -0.13
Net Cash From Financing Activities
26 122 25 9.90 212 0.01 142 14 - 25
Net Cash From Continuing Financing Activities
26 122 25 9.90 212 0.01 142 14 - 25
Issuance of Debt
25 122 25 9.90 39 - 141 0.00 - -
Other Financing Activities, net
1.30 0.28 - - 173 0.01 - - - -
Cash Interest Paid
4.82 4.66 4.08 3.74 2.91 2.91 2.76 2.55 2.10 2.02

Annual Balance Sheets for Phathom Pharmaceuticals

This table presents Phathom Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Total Assets
378 414 165
Total Current Assets
360 397 161
Cash & Equivalents
297 381 155
Restricted Cash
2.86 2.86 0.51
Accounts Receivable
39 1.64 0.00
Inventories, net
3.21 1.21 0.00
Prepaid Expenses
21 13 5.13
Plant, Property, & Equipment, net
1.48 2.15 1.21
Total Noncurrent Assets
14 11 2.59
Other Noncurrent Operating Assets
14 11 2.59
Total Liabilities & Shareholders' Equity
378 414 165
Total Liabilities
632 487 240
Total Current Liabilities
86 39 26
Accounts Payable
11 13 10.00
Accrued Expenses
53 17 15
Current Deferred Revenue
20 7.11 0.00
Other Current Liabilities
0.50 0.73 0.71
Other Current Nonoperating Liabilities
1.71 1.15 0.85
Total Noncurrent Liabilities
546 448 213
Long-Term Debt
201 138 95
Noncurrent Deferred Revenue
333 300 110
Other Noncurrent Operating Liabilities
12 10 8.60
Commitments & Contingencies
0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-254 -73 -75
Total Preferred & Common Equity
-254 -73 -75
Preferred Stock
0.00 0.00 0.00
Total Common Equity
-254 -73 -75
Common Stock
1,009 856 652
Retained Earnings
-1,263 -929 -727
Treasury Stock
0.00 0.00 0.00

Quarterly Balance Sheets for Phathom Pharmaceuticals

This table presents Phathom Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets
387 319 356 237 265 144 202
Total Current Assets
374 305 340 227 258 140 198
Cash & Equivalents
335 276 322 214 249 130 197
Restricted Cash
2.86 2.86 2.87 - - - -
Accounts Receivable
21 11 3.88 - - - -
Inventories, net
3.11 2.18 1.46 0.11 0.11 - -
Prepaid Expenses
15 15 13 13 8.76 10 0.98
Plant, Property, & Equipment, net
1.66 1.81 1.96 1.98 1.16 1.28 0.83
Total Noncurrent Assets
8.71 9.91 11 8.29 6.16 2.89 3.29
Other Noncurrent Operating Assets
8.71 9.91 11 8.29 6.16 2.89 3.29
Total Liabilities & Shareholders' Equity
387 319 356 237 265 144 202
Total Liabilities
574 553 505 255 247 234 228
Total Current Liabilities
65 47 43 24 22 14 23
Accounts Payable
7.13 7.66 8.40 5.79 4.17 4.81 7.14
Accrued Expenses
36 27 17 14 15 8.02 13
Current Deferred Revenue
20 9.91 16 2.39 0.28 - -
Other Current Liabilities
0.68 0.72 0.73 0.72 0.72 0.71 1.63
Other Current Nonoperating Liabilities
1.52 1.43 1.31 0.96 0.93 0.91 0.69
Total Noncurrent Liabilities
509 506 462 231 226 220 205
Long-Term Debt
176 174 149 99 98 97 94
Noncurrent Deferred Revenue
322 321 303 123 120 - -
Other Noncurrent Operating Liabilities
11 11 9.99 8.13 8.29 123 112
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-187 -234 -149 -18 18 -90 -26
Total Preferred & Common Equity
-187 -234 -149 -18 18 -90 -26
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
-187 -234 -149 -18 18 -90 -26
Common Stock
1,001 869 863 831 823 675 646
Retained Earnings
-1,189 -1,103 -1,012 -849 -806 -765 -672
Treasury Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00

Annual Metrics And Ratios for Phathom Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Phathom Pharmaceuticals' official financial filings.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Growth Metrics
- - -
Revenue Growth
8,001.47% 0.00% 0.00%
EBITDA Growth
-66.31% 2.81% -27.67%
EBIT Growth
-65.66% 2.93% -25.82%
NOPAT Growth
-65.84% 2.97% -27.66%
Net Income Growth
-65.84% -1.96% -37.42%
EPS Growth
-34.61% 22.18% -29.82%
Operating Cash Flow Growth
-93.90% 6.11% 1.30%
Free Cash Flow Firm Growth
-343.76% 1,037.16% 94.08%
Invested Capital Growth
-10.24% -136.30% -542.26%
Revenue Q/Q Growth
110.32% 0.00% 0.00%
EBITDA Q/Q Growth
3.72% -16.25% -8.74%
EBIT Q/Q Growth
3.65% -16.04% -8.61%
NOPAT Q/Q Growth
3.63% -16.13% -8.56%
Net Income Q/Q Growth
1.51% -13.85% -10.77%
EPS Q/Q Growth
7.84% -2.88% -8.14%
Operating Cash Flow Q/Q Growth
-7.96% -2.04% 0.15%
Free Cash Flow Firm Q/Q Growth
-1,205.84% 167.46% 53.16%
Invested Capital Q/Q Growth
-0.92% -142.34% -4.58%
Profitability Metrics
- - -
Gross Margin
85.57% 75.51% 0.00%
EBITDA Margin
-496.79% -24,200.59% 0.00%
Operating Margin
-502.18% -24,532.55% 0.00%
EBIT Margin
-502.20% -24,560.12% 0.00%
Profit (Net Income) Margin
-605.09% -29,558.94% 0.00%
Tax Burden Percent
100.00% 100.00% 100.00%
Interest Burden Percent
120.49% 120.35% 114.59%
Effective Tax Rate
0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00%
Return on Equity (ROE)
204.89% 273.21% 14,877.58%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
-70.06% -57.89% 0.00%
Return on Assets (ROA)
-84.41% -69.68% 0.00%
Return on Common Equity (ROCE)
204.89% 273.21% 14,877.58%
Return on Equity Simple (ROE_SIMPLE)
131.84% 277.07% 264.29%
Net Operating Profit after Tax (NOPAT)
-194 -117 -121
NOPAT Margin
-351.53% -17,172.79% 0.00%
Net Nonoperating Expense Percent (NNEP)
-81.86% -55.39% -100.75%
Return On Investment Capital (ROIC_SIMPLE)
372.29% -179.95% -
Cost of Revenue to Revenue
14.43% 24.49% 0.00%
SG&A Expenses to Revenue
526.07% 17,291.50% 0.00%
R&D to Revenue
61.68% 7,316.57% 0.00%
Operating Expenses to Revenue
587.75% 24,608.06% 0.00%
Earnings before Interest and Taxes (EBIT)
-277 -168 -173
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-274 -165 -170
Valuation Ratios
- - -
Price to Book Value (P/BV)
0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00
Price to Revenue (P/Rev)
10.05 766.45 0.00
Price to Earnings (P/E)
0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
8.26 405.13 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 4.17 0.00
Leverage & Solvency
- - -
Debt to Equity
-0.79 -1.89 -1.27
Long-Term Debt to Equity
-0.79 -1.89 -1.27
Financial Leverage
1.05 2.07 57.52
Leverage Ratio
-2.43 -3.92 -133.27
Compound Leverage Factor
-2.92 -4.72 -152.72
Debt to Total Capital
-386.06% 211.79% 465.84%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
-386.06% 211.79% 465.84%
Preferred Equity to Total Capital
0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00%
Common Equity to Total Capital
486.06% -111.79% -365.84%
Debt to EBITDA
-0.73 -0.84 -0.56
Net Debt to EBITDA
0.36 1.49 0.36
Long-Term Debt to EBITDA
-0.73 -0.84 -0.56
Debt to NOPAT
-1.04 -1.18 -0.79
Net Debt to NOPAT
0.51 2.10 0.50
Long-Term Debt to NOPAT
-1.04 -1.18 -0.79
Altman Z-Score
-5.55 -2.79 -7.48
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00%
Liquidity Ratios
- - -
Current Ratio
4.20 10.25 6.12
Quick Ratio
3.92 9.88 5.92
Cash Flow Metrics
- - -
Free Cash Flow to Firm (FCFF)
-162 66 -7.08
Operating Cash Flow to CapEx
-197,607.41% -8,419.83% -14,075.89%
Free Cash Flow to Firm to Interest Expense
-2.25 1.58 -0.26
Operating Cash Flow to Interest Expense
-3.70 -3.28 -5.37
Operating Cash Flow Less CapEx to Interest Expense
-3.71 -3.32 -5.40
Efficiency Ratios
- - -
Asset Turnover
0.14 0.00 0.00
Accounts Receivable Turnover
2.73 0.00 0.00
Inventory Turnover
3.61 0.00 0.00
Fixed Asset Turnover
30.51 0.41 0.00
Accounts Payable Turnover
0.69 0.01 0.00
Days Sales Outstanding (DSO)
133.56 0.00 0.00
Days Inventory Outstanding (DIO)
101.08 0.00 0.00
Days Payable Outstanding (DPO)
528.94 24,695.42 0.00
Cash Conversion Cycle (CCC)
-294.30 -24,695.42 0.00
Capital & Investment Metrics
- - -
Invested Capital
-351 -318 -135
Invested Capital Turnover
-0.17 0.00 0.00
Increase / (Decrease) in Invested Capital
-33 -183 -114
Enterprise Value (EV)
457 276 406
Market Capitalization
555 523 467
Book Value per Share
($3.71) ($1.27) ($1.80)
Tangible Book Value per Share
($3.71) ($1.27) ($1.80)
Total Capital
-52 65 20
Total Debt
201 138 95
Total Long-Term Debt
201 138 95
Net Debt
-99 -246 -61
Capital Expenditures (CapEx)
0.14 1.63 1.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-26 -26 -22
Debt-free Net Working Capital (DFNWC)
274 359 134
Net Working Capital (NWC)
274 359 134
Net Nonoperating Expense (NNE)
140 84 77
Net Nonoperating Obligations (NNO)
-97 -245 -60
Total Depreciation and Amortization (D&A)
2.99 2.45 2.73
Debt-free, Cash-free Net Working Capital to Revenue
-46.55% -3,754.40% 0.00%
Debt-free Net Working Capital to Revenue
496.64% 52,588.12% 0.00%
Net Working Capital to Revenue
496.64% 52,588.12% 0.00%
Earnings Adjustments
- - -
Adjusted Basic Earnings per Share
($5.29) $0.00 ($5.05)
Adjusted Weighted Average Basic Shares Outstanding
63.18M 0.00 39.12M
Adjusted Diluted Earnings per Share
($5.29) $0.00 ($5.05)
Adjusted Weighted Average Diluted Shares Outstanding
63.18M 0.00 39.12M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
69.64M 0.00 41.97M
Normalized Net Operating Profit after Tax (NOPAT)
-194 -117 -121
Normalized NOPAT Margin
-351.53% -17,172.79% 0.00%
Pre Tax Income Margin
-605.09% -29,558.94% 0.00%
Debt Service Ratios
- - -
EBIT to Interest Expense
-3.85 -3.99 -6.32
NOPAT to Interest Expense
-2.70 -2.79 -4.42
EBIT Less CapEx to Interest Expense
-3.86 -4.03 -6.36
NOPAT Less CapEx to Interest Expense
-2.70 -2.83 -4.46
Payout Ratios
- - -
Dividend Payout Ratio
0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Phathom Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Phathom Pharmaceuticals' official financial filings.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics
- - - - - - - - - -
Revenue Growth
4,249.56% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
15.32% -98.97% -144.74% -135.62% -50.08% 15.81% 29.95% 21.07% -42.12% -27.97%
EBIT Growth
15.05% -97.47% -143.88% -132.88% -49.55% 15.71% 30.13% 20.72% -41.37% -20.90%
NOPAT Growth
14.97% -98.54% -143.84% -132.58% -49.81% 16.15% 30.12% 20.65% -41.17% -28.34%
Net Income Growth
6.43% -97.90% -123.23% -119.10% -44.55% 15.36% 19.55% 7.01% -53.65% -39.36%
EPS Growth
31.25% -73.68% -85.71% -59.55% -8.27% 42.42% 36.84% 16.82% -40.00% -34.69%
Operating Cash Flow Growth
-44.89% -99.20% -218.56% -73.99% -6.72% 8.86% 13.67% 11.37% 0.54% -20.47%
Free Cash Flow Firm Growth
-106.72% 842.99% 1,458.93% 64.18% 66.12% -133.82% -118.43% 310.67% 268.36% 586.46%
Invested Capital Growth
-10.24% -164.72% -154.37% -164.50% -136.30% -1.97% -9.16% -1,331.65% -542.26% -294.56%
Revenue Q/Q Growth
81.41% 123.27% 283.05% 180.35% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
16.39% 8.60% -10.53% -0.25% -96.45% -12.43% -6.42% 36.15% -10.21% 6.45%
EBIT Q/Q Growth
16.15% 8.41% -10.44% -0.15% -94.92% -13.12% -5.46% 35.68% -9.85% 6.23%
NOPAT Q/Q Growth
16.07% 8.41% -10.50% -0.11% -95.95% -12.49% -5.40% 35.52% -9.67% 6.25%
Net Income Q/Q Growth
13.00% 6.42% -10.37% -4.12% -84.01% -5.56% -8.33% 31.31% -7.74% -0.34%
EPS Q/Q Growth
25.00% 15.38% -9.86% 1.39% -89.47% 9.52% 5.62% 33.08% -0.76% 0.75%
Operating Cash Flow Q/Q Growth
0.18% 10.11% -2.46% -57.59% -37.23% -43.76% 44.04% 3.34% -17.21% -36.16%
Free Cash Flow Firm Q/Q Growth
-105.42% 10.74% -1.07% 13.05% 699.92% -102.54% -111.95% 14.38% 22.13% 10.35%
Invested Capital Q/Q Growth
-0.92% -3.06% -4.27% -1.65% -142.34% 0.97% -8.42% 9.19% -4.58% -6.02%
Profitability Metrics
- - - - - - - - - -
Gross Margin
87.14% 85.59% 81.21% 77.72% 75.51% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
-197.36% -428.23% -1,046.00% -3,624.95% -10,137.54% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
-200.30% -432.95% -1,055.43% -3,658.68% -10,245.60% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
-200.13% -433.00% -1,055.52% -3,660.93% -10,247.65% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
-250.98% -523.34% -1,248.58% -4,333.26% -11,667.16% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent
125.41% 120.86% 118.29% 118.37% 113.85% 120.60% 129.24% 125.81% 117.79% 120.10%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
204.89% 331.35% 274.81% 206.65% 273.21% 801.29% -3,489.00% 747.21% 14,877.58% -463.29%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
-27.92% -36.46% -35.83% -37.95% -24.16% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
-35.01% -44.06% -42.38% -44.92% -27.50% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
204.89% 331.35% 274.81% 206.65% 273.21% 801.29% -3,489.00% 747.21% 14,877.58% -463.29%
Return on Equity Simple (ROE_SIMPLE)
0.00% 181.41% 127.06% 166.08% 0.00% 996.28% -1,050.66% 216.06% 0.00% 675.56%
Net Operating Profit after Tax (NOPAT)
-42 -50 -54 -49 -49 -25 -22 -21 -33 -30
NOPAT Margin
-140.21% -303.07% -738.80% -2,561.08% -7,171.92% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-19.20% -26.32% -29.47% -32.77% -20.10% -16.95% -14.20% -42.65% -29.30% -17.89%
Return On Investment Capital (ROIC_SIMPLE)
79.72% - - - -75.15% - - - - -
Cost of Revenue to Revenue
12.86% 14.41% 18.79% 22.28% 24.49% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
258.51% 465.38% 1,035.94% 3,243.20% 8,357.33% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
28.93% 53.16% 100.71% 493.20% 1,963.78% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
287.44% 518.54% 1,136.65% 3,736.40% 10,321.11% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-59 -71 -77 -70 -70 -36 -32 -30 -47 -43
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-59 -70 -77 -69 -69 -35 -31 -29 -46 -42
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 0.00 0.00 0.00 0.00 35.49 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 35.49 0.00 0.00 0.00
Price to Revenue (P/Rev)
10.05 41.01 60.73 239.41 766.45 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
8.26 34.86 50.18 171.53 405.13 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 62.63 18.02 7.94 4.17 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
-0.79 -0.94 -0.75 -1.00 -1.89 -5.58 5.56 -1.07 -1.27 -3.55
Long-Term Debt to Equity
-0.79 -0.94 -0.75 -1.00 -1.89 -5.58 5.56 -1.07 -1.27 -3.55
Financial Leverage
1.05 1.34 1.17 0.87 2.07 4.88 -24.95 1.51 57.52 -3.09
Leverage Ratio
-2.43 -3.05 -2.70 -2.10 -3.92 -9.93 45.15 -5.62 -133.27 5.58
Compound Leverage Factor
-3.04 -3.68 -3.20 -2.48 -4.46 -11.98 58.34 -7.07 -156.99 6.71
Debt to Total Capital
-386.06% -1,543.78% -293.61% 28,658.27% 211.79% 121.81% 84.75% 1,499.89% 465.84% 139.17%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
-386.06% -1,543.78% -293.61% 28,658.27% 211.79% 121.81% 84.75% 1,499.89% 465.84% 139.17%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
486.06% 1,643.78% 393.61% -28,558.27% -111.79% -21.81% 15.25% -1,399.89% -365.84% -39.17%
Debt to EBITDA
-0.73 -0.62 -0.70 -0.73 -0.84 -0.70 -0.66 -0.60 -0.56 -0.60
Net Debt to EBITDA
0.36 0.57 0.42 0.86 1.49 0.81 1.02 0.20 0.36 0.66
Long-Term Debt to EBITDA
-0.73 -0.62 -0.70 -0.73 -0.84 -0.70 -0.66 -0.60 -0.56 -0.60
Debt to NOPAT
-1.04 -0.87 -0.99 -1.03 -1.18 -0.98 -0.93 -0.84 -0.79 -0.84
Net Debt to NOPAT
0.51 0.80 0.59 1.21 2.10 1.13 1.43 0.29 0.50 0.93
Long-Term Debt to NOPAT
-1.04 -0.87 -0.99 -1.03 -1.18 -0.98 -0.93 -0.84 -0.79 -0.84
Altman Z-Score
-3.65 -2.75 -3.98 -2.88 -2.01 -3.10 -2.07 -6.31 -4.97 -3.17
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
4.20 5.73 6.48 7.83 10.25 9.46 11.96 9.68 6.12 8.65
Quick Ratio
3.92 5.45 6.11 7.50 9.88 8.91 11.55 8.97 5.92 8.60
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-9.03 167 150 152 135 -22 -11 93 81 66
Operating Cash Flow to CapEx
-1,269,120.00% -144,484.09% -153,741.30% -172,550.00% -9,220.42% -3,398.72% -370,000.00% -18,536.92% -9,961.41% -26,131.34%
Free Cash Flow to Firm to Interest Expense
-0.49 9.01 8.47 8.86 10.33 -2.22 -1.15 10.05 8.43 7.15
Operating Cash Flow to Interest Expense
-3.41 -3.44 -3.98 -4.02 -3.36 -3.16 -2.31 -4.30 -4.27 -3.77
Operating Cash Flow Less CapEx to Interest Expense
-3.41 -3.44 -3.98 -4.02 -3.40 -3.25 -2.31 -4.33 -4.32 -3.79
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.14 0.08 0.03 0.01 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
2.73 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
3.61 2.68 1.72 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
30.51 14.47 6.68 1.60 0.41 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.69 0.67 0.33 0.09 0.01 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
133.56 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
101.08 135.96 212.07 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
528.94 545.47 1,096.48 4,064.86 24,695.42 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
-294.30 -409.52 -884.42 -4,064.86 -24,695.42 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
-351 -347 -337 -323 -318 -131 -133 -122 -135 -129
Invested Capital Turnover
-0.17 -0.11 -0.04 -0.01 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
-33 -216 -205 -201 -183 -2.54 -11 -114 -114 -96
Enterprise Value (EV)
457 916 498 445 276 475 474 267 406 331
Market Capitalization
555 1,077 602 621 523 589 625 300 467 434
Book Value per Share
($3.71) ($3.14) ($4.00) ($2.54) ($1.27) ($0.31) $0.40 ($2.15) ($1.80) ($0.67)
Tangible Book Value per Share
($3.71) ($3.14) ($4.00) ($2.54) ($1.27) ($0.31) $0.40 ($2.15) ($1.80) ($0.67)
Total Capital
-52 -11 -59 0.52 65 81 115 6.44 20 67
Total Debt
201 176 174 149 138 99 98 97 95 94
Total Long-Term Debt
201 176 174 149 138 99 98 97 95 94
Net Debt
-99 -162 -105 -176 -246 -114 -151 -33 -61 -103
Capital Expenditures (CapEx)
0.01 0.04 0.05 0.04 0.48 0.94 0.01 0.21 0.41 0.13
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-26 -29 -21 -28 -26 -11 -13 -4.17 -22 -22
Debt-free Net Working Capital (DFNWC)
274 309 258 297 359 203 236 125 134 175
Net Working Capital (NWC)
274 309 258 297 359 203 236 125 134 175
Net Nonoperating Expense (NNE)
33 36 37 34 31 18 19 17 22 21
Net Nonoperating Obligations (NNO)
-97 -160 -103 -175 -245 -113 -150 -32 -60 -102
Total Depreciation and Amortization (D&A)
0.82 0.78 0.70 0.69 0.75 0.66 0.40 0.64 0.67 0.74
Debt-free, Cash-free Net Working Capital to Revenue
-46.55% -110.42% -214.97% -1,088.70% -3,754.40% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
496.64% 1,174.47% 2,599.10% 11,443.91% 52,588.12% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
496.64% 1,174.47% 2,599.10% 11,443.91% 52,588.12% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
($0.99) ($1.32) ($1.56) ($1.42) ($1.44) ($0.76) ($0.84) ($0.89) ($1.33) $0.00
Adjusted Weighted Average Basic Shares Outstanding
63.18M 64.63M 58.56M 58.37M 51.29M 56.78M 48.50M 42.35M 39.12M 0.00
Adjusted Diluted Earnings per Share
($0.99) ($1.32) ($1.56) ($1.42) ($1.44) ($0.76) ($0.84) ($0.89) ($1.33) $0.00
Adjusted Weighted Average Diluted Shares Outstanding
63.18M 64.63M 58.56M 58.37M 51.29M 56.78M 48.50M 42.35M 39.12M 0.00
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
69.64M 68.38M 59.59M 58.54M 58.48M 57.25M 56.80M 43.61M 41.97M 0.00
Normalized Net Operating Profit after Tax (NOPAT)
-42 -50 -54 -49 -49 -25 -22 -21 -33 -30
Normalized NOPAT Margin
-140.21% -303.07% -738.80% -2,561.08% -7,171.92% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
-250.98% -523.34% -1,248.58% -4,333.26% -11,667.16% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
-3.19 -3.83 -4.35 -4.08 -5.36 -3.55 -3.30 -3.26 -4.87 -4.59
NOPAT to Interest Expense
-2.24 -2.68 -3.05 -2.85 -3.75 -2.47 -2.31 -2.28 -3.40 -3.21
EBIT Less CapEx to Interest Expense
-3.19 -3.83 -4.35 -4.08 -5.40 -3.64 -3.30 -3.28 -4.91 -4.60
NOPAT Less CapEx to Interest Expense
-2.24 -2.68 -3.05 -2.85 -3.79 -2.56 -2.31 -2.31 -3.44 -3.22
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Phathom Pharmaceuticals' Financials

When does Phathom Pharmaceuticals's fiscal year end?

According to the most recent income statement we have on file, Phathom Pharmaceuticals' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Phathom Pharmaceuticals' net income changed over the last 2 years?

Phathom Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$334.33 million in 2024, rising from -$197.72 million in 2022. The previous period was -$201.59 million in 2023. See Phathom Pharmaceuticals' forecast for analyst expectations on what’s next for the company.

What is Phathom Pharmaceuticals's operating income?
Phathom Pharmaceuticals's total operating income in 2024 was -$277.47 million, based on the following breakdown:
  • Total Gross Profit: $47.28 million
  • Total Operating Expenses: $324.75 million
How has Phathom Pharmaceuticals revenue changed over the last 2 years?

Over the last 2 years, Phathom Pharmaceuticals' total revenue changed from $0.00 in 2022 to $55.25 million in 2024, a change of 5,525,200,000.0%.

How much debt does Phathom Pharmaceuticals have?

Phathom Pharmaceuticals' total liabilities were at $631.90 million at the end of 2024, a 29.9% increase from 2023, and a 163.7% increase since 2022.

How much cash does Phathom Pharmaceuticals have?

In the past 2 years, Phathom Pharmaceuticals' cash and equivalents has ranged from $155.39 million in 2022 to $381.39 million in 2023, and is currently $297.26 million as of their latest financial filing in 2024.

How has Phathom Pharmaceuticals' book value per share changed over the last 2 years?

Over the last 2 years, Phathom Pharmaceuticals' book value per share changed from -1.80 in 2022 to -3.71 in 2024, a change of 106.3%.



This page (NASDAQ:PHAT) was last updated on 6/5/2025 by MarketBeat.com Staff
From Our Partners